Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment

Authors

  • Alexandra V. Lucs PhD,

    1. The Feinstein Institute for Medical Research, Manhasset, New York
    Search for more papers by this author
  • Benjamin Saltman MD,

    1. Department of Otolaryngology, Hofstra North Shore–Long Island Jewish School of Medicine, New Hyde Park, New York
    Search for more papers by this author
    • The first 2 authors contributed equally to this work.

  • Christine H. Chung MD,

    1. Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Search for more papers by this author
  • Bettie M. Steinberg PhD,

    1. The Feinstein Institute for Medical Research, Manhasset, New York
    2. Department of Otolaryngology, Hofstra North Shore–Long Island Jewish School of Medicine, New Hyde Park, New York
    Search for more papers by this author
  • David L. Schwartz MD

    Corresponding author
    1. The Feinstein Institute for Medical Research, Manhasset, New York
    2. Department of Otolaryngology, Hofstra North Shore–Long Island Jewish School of Medicine, New Hyde Park, New York
    3. Department of Radiation Medicine, Hofstra North Shore–Long Island Jewish School of Medicine, New Hyde Park, New York
    • The Feinstein Institute for Medical Research, Manhasset, New York
    Search for more papers by this author

  • Bettie M. Steinberg has a conflict of interest from a research grant from Pfizer, Inc. of celecoxib for a clincial trial for recurrent respiratory papillomatosis.

Abstract

Head and neck oncologists have traditionally relied on clinical tumor features and patient characteristics to guide care of individual patients. As surgical, radiotherapeutic, and systemic treatments have evolved to become more anatomically precise and mechanistically specific, the opportunity for improved cure and functional patient recovery has never been more promising for this historically debilitating cancer. However, personalized treatment must be accompanied by sophisticated patient selection to triage the application of advanced therapies toward ideal patient candidates. In this monograph, we review current progress, investigative themes, and key challenges facing head and neck cancer biomarker development intended to make personalized head and neck cancer treatment a clinical reality. © 2012 Wiley Periodicals, Inc. Head Neck, 2013

Ancillary